'Least Burdensome' Provisions Revisited In FDA Regulatory Science Report
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking to rein in the device industry's interpretation of the "least burdensome" statutory provisions, which govern how much data regulators may ask for during pre-market reviews
You may also be interested in...
Senate Bill Tackles 'Least Burdensome,' Centralized IRBs, CLIA Waivers
The targeted FDA Device Accountability Act mirrors select device sections of the House 21st Century Cures legislation seeking to strengthen the use of "least-burdensome" provisions, allow use of centralized IRBs for device trials and refining standards for diagnostic CLIA waivers.
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
FDA says some of its new "notice-to-industry" letters will have the same force as agency guidance documents that take effect immediately.
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
FDA says some of its new "notice-to-industry" letters will have the same force as agency guidance documents that take effect immediately.